Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s MHRA, allowing the single-dose vaccine to be made ...

Valneva's Ixchiq is the first and only approved Chikungunya vaccine in the US, Canada, and EU. Ixiaro is for Japanese encephalitis, and it’s today VALN’s main revenue contributor. But its near ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use ...

Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing ...

The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada ...

(MENAFN- GlobeNewsWire - Nasdaq) Saint Herblain (France), February 5, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Medicines and ...

The single-dose vaccine is indicated for active immunization ... the European Medicines Agency (EMA) and Health Canada 6 to potentially extend the use of IXCHIQ ® to adolescents aged 12 to 17 years.

The vaccine is manufactured at Valneva’s leading vaccine production site in Livingston, Scotland. The approval is based on IXCHIQ®’s final pivotal Phase 3 data, published in The Lancet ...